Back to Search
Start Over
A novel plant‐made monoclonal antibody enhances the synergetic potency of an antibody cocktail against the SARS‐CoV‐2 Omicron variant.
- Source :
- Plant Biotechnology Journal; Mar2023, Vol. 21 Issue 3, p549-559, 11p
- Publication Year :
- 2023
-
Abstract
- Summary: This study describes a novel, neutralizing monoclonal antibody (mAb), 11D7, discovered by mouse immunization and hybridoma generation, against the parental Wuhan‐Hu‐1 RBD of SARS‐CoV‐2. We further developed this mAb into a chimeric human IgG and recombinantly expressed it in plants to produce a mAb with human‐like, highly homogenous N‐linked glycans that has potential to impart greater potency and safety as a therapeutic. The epitope of 11D7 was mapped by competitive binding with well‐characterized mAbs, suggesting that it is a Class 4 RBD‐binding mAb that binds to the RBD outside the ACE2 binding site. Of note, 11D7 maintains recognition against the B.1.1.529 (Omicron) RBD, as well neutralizing activity. We also provide evidence that this novel mAb may be useful in providing additional synergy to established antibody cocktails, such as Evusheld™ containing the antibodies tixagevimab and cilgavimab, against the Omicron variant. Taken together, 11D7 is a unique mAb that neutralizes SARS‐CoV‐2 through a mechanism that is not typical among developed therapeutic mAbs and by being produced in ΔXFT Nicotiana benthamiana plants, highlights the potential of plants to be an economic and safety‐friendly alternative platform for generating mAbs to address the evolving SARS‐CoV‐2 crisis. [ABSTRACT FROM AUTHOR]
- Subjects :
- SARS-CoV-2 Omicron variant
MONOCLONAL antibodies
IMMUNOGLOBULINS
Subjects
Details
- Language :
- English
- ISSN :
- 14677644
- Volume :
- 21
- Issue :
- 3
- Database :
- Complementary Index
- Journal :
- Plant Biotechnology Journal
- Publication Type :
- Academic Journal
- Accession number :
- 162030390
- Full Text :
- https://doi.org/10.1111/pbi.13970